Received Oct 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | IM |
blister at the injection site; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of injection site blisters in a 67-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received first dose on an unknown date). On 12-SEP-2025, the patient received the 2nd dose of Shingrix (intramuscular, unknown deltoid). On 14-SEP-2025, 2 days after receiving Shingrix, the patient experienced injection site blisters (Verbatim: blister at the injection site). The outcome of the injection site blisters was not resolved. It was unknown if the reporter considered the injection site blisters to be related to Shingrix. It was unknown if the company considered the injection site blisters to be related to Shingrix. Additional Information: GSK Receipt Date: 15-SEP-2025 The pharmacist reported that the patient had received the Shingrix vaccine and had noticed a blister at the injection site, which was described as a shiny bubble, half the size of a dime (0.67 millimeter). The batch number was not provided and a request for this information has been made.